Ripronat (Injections / Capsules)  
(Trimethylhydrazinium Propionate)

**CONTENT:**
Capsules. Capsule of Ripronat contains 3-(2,2,2-trimethylhydrazinium) propionate dihydrate 250 mg or 500 mg.  
Ampoules. Ampoule of Ripronat contains 3-(2,2,2-trimethylhydrazinium) propionate dihydrate 500 mg.

**PHARMACOLOGICAL PROPERTIES:**  
Ripronat is a structural analog of y-butyrobetaine - carnitine precursor. Carrying out the functions of y-butyrobetaine, it accelerates nerve impulse transmission in a human body. As the result all mental reactions are accelerated, general metabolism is improved, a tonic effect is observed. There are memory improvements, acceleration of performance of mental tasks, dexterity increasing, and physical performance. It attenuates mental and exercise stress.  
By inhibiting y-butyrobetainehydroxylase the medicine decreases biosynthesis of carnitine and transport of long chain fatty acids through cell membranes, prevents accumulation of activated forms of unoxidized fatty acids - derivatives of acylcarnitine and acylcoenzyme A, thus stopping their harmful action. In conditions of ischemia it restores the balance between delivery and cells oxygen demand. As the result of decrease of carnitine concentration y-butyrobetaine (which has vasodilating properties) is intensively synthesized. It delays tissue necrosis, accelerates rehabilitation period in acute myocardial infarction. It improves myocardial contractility and increases exercise tolerance in cardiac insufficiency. The medicine can eliminates the functional disturbances of somatic and autonomic nervous system in patients with chronic alcoholism in the period of abstinence. It is well-absorbed following oral administration.

**THERAPEUTIC INDICATIONS:**  
- complex therapy of IHD (angina, myocardial infarction), chronic cardiac insufficiency and dyshormonal cardiomyopathy;  
- complex therapy of acute and chronic cerebral circulation abnormalities (cerebral strokes and cerebrovascular deficiency);  
- decreased capacity for work, athletic overexertion (including sportsmen);  
- for acceleration of rehabilitation in post surgery period;  
- abstinence syndrome in chronic alcoholism (in combination with a specific therapy of alcoholism).

**CONTRAINDICATIONS:**  
- hypersensitization to the medicine;  
- elevation of intracranial pressure (including, in disorders of venous outflow, intracranial tumor).  
There are no sufficient data about safety and efficacy of Ripronat use in children under 12 years old.
DOSAGE AND ADMINISTRATION:
Due to an excitory effect it is recommended to administer the medicine in the first half of the day.
In cardiovascular diseases as a combined therapy the medicine is prescribed as follows: 500-1000 mg/daily as a single dose or divided in two doses. The course of treatment is 4-6 weeks.
In cardialgia associated with dyshormonal cardiomyopathy Ripronat is prescribed in dose 250 mg 2 times daily. The course of treatment is 12 days. In cerebral circulation abnormalities in acute phase the medicine is prescribed intravenously in 500 mg/daily during 10 days, then orally 500-1000 mg/daily. The total therapy course is 4-6 weeks. In chronic cerebral circulation abnormalities the medicine is taken in dose 500 mg/daily. The total therapy course 4-6 weeks. The repeated courses are prescribed individually 2-3 times a year.
In mental and physical stress it is prescribed orally 250 mg 4 times daily. The course of treatment is 10-14 days. Repeat the therapy in 2-3 weeks if necessary.
For sportsmen it is recommended to take 500-1000 mg 2 times daily before training. The duration of course in training period is 14-21 days; during competitions is 10-14 days.
In chronic alcoholism the medicine is prescribed in 500 mg 4 times daily. The course of treatment is 7-10 days.

PACKAGING:
10 capsules 250 mg in blister. 4 or 6 blisters with the leaflet in carton box. 15 capsules 500 mg in blister. 4 blisters with the leaflet in carton box. 10 ampoules with leaflet in carton box.